These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Drugs for percutaneous coronary interventions. Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527 [TBL] [Abstract][Full Text] [Related]
25. [Platelet antiaggregants: a review of their indications in primary care]. Blasco Valle M; Vitoria Lapeña A; Robledo E Aten Primaria; 1993 Feb; 11(3):142-6, 148-50. PubMed ID: 8453007 [No Abstract] [Full Text] [Related]
26. [Anticoagulants and antiaggregants in ischemic heart disease]. Motolese M G Ital Cardiol; 1990 Aug; 20(8):746-57. PubMed ID: 2272424 [No Abstract] [Full Text] [Related]
27. Cardiovascular effects of Danshen. Cheng TO Int J Cardiol; 2007 Sep; 121(1):9-22. PubMed ID: 17363091 [TBL] [Abstract][Full Text] [Related]
28. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Wiviott SD Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236 [TBL] [Abstract][Full Text] [Related]
30. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
31. Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? Milani RV Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S7-S11. PubMed ID: 19213064 [TBL] [Abstract][Full Text] [Related]
32. What physicians should know about coronary stents. Rihal CS Minn Med; 2008 Jan; 91(1):44-6. PubMed ID: 18269069 [TBL] [Abstract][Full Text] [Related]
33. Platelet inhibitor agents in cardiovascular disease: an update. Stein B; Fuster V; Israel DH; Cohen M; Badimon L; Badimon JJ; Chesebro JH J Am Coll Cardiol; 1989 Oct; 14(4):813-36. PubMed ID: 2677086 [TBL] [Abstract][Full Text] [Related]
34. Optimal medical management around the time of surgery. Voûte MT; Winkel TA; Poldermans D Heart; 2010 Nov; 96(22):1842-8. PubMed ID: 20965994 [No Abstract] [Full Text] [Related]
35. [Clinical assessment of the preventive use of antiplatelet drugs]. Lozano Almela ML; Vicente García V Rev Clin Esp; 2004 Feb; 204(2):106-8. PubMed ID: 15023312 [No Abstract] [Full Text] [Related]
36. [Endothelium as a target for new therapeutic strategies in cerebral vascular diseases]. Putilina MV Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):122-130. PubMed ID: 29171500 [TBL] [Abstract][Full Text] [Related]
39. [Antiaggregants in Primary Prevention of Cardiovascular Diseases and Prevention of Atherothrombosis in Patients With Stable Ischemic Heart Disease: Aspects of Efficacy and Safety]. Perepech NB; Mikhaylova IE Kardiologiia; 2018 Feb; (2):55-67. PubMed ID: 29466201 [TBL] [Abstract][Full Text] [Related]
40. [Antiplatelet therapy and dermatological surgery]. Sei JF Ann Dermatol Venereol; 2007 Oct; 134(10 Pt 1):729-30. PubMed ID: 17978708 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]